Latest news
Morgan Stanley Maintains Insmed(INSM.US) With Buy Rating, Raises Target Price to $218 - MoomooMoomoo · Fri, 07 Aug 2026 15:39:30 GMTInsmed (INSM): Brinsupri Outperformance and Raised Sales Guidance Support Buy Rating - TipRanksTipRanks · Fri, 07 Aug 2026 09:22:31 GMTInsmed reports Q2 EPS (6c) vs. ($1.70) last year - TipRanksTipRanks · Thu, 06 Aug 2026 19:03:57 GMTMatt Phipps Reiterates Buy on Insmed as Brinsupri Outperformance, Raised Guidance and Higher Peak Sales Outlook Strengthen Long-Term Growth Story - TipRanksTipRanks · Thu, 06 Aug 2026 18:36:05 GMTWhy Insmed’s Hot Drug Launch Isn’t Saving the Stock - TipRanksTipRanks · Thu, 06 Aug 2026 13:08:36 GMTInsmed (IM8N) Q1 2023 Earnings Report - Results, Call & Slides - TipRanksTipRanks · Sun, 02 Aug 2026 09:53:01 GMT